Qurient Co

Qurient Co ROE

The Return on Equity (ROE) of Qurient Co (115180.KQ) as of Nov 17, 2026 is -88.28 %. In the previous year, Return on Equity (ROE) was -40.92 % — a change of 115.77% (lower).

ROE

-88.28 %

YoY

115.77%

Last updated:

In 2025, Qurient Co's return on equity (ROE) was -88.28 %, a 115.77% increase from the -40.92 % ROE in the previous year.

The Qurient Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-41.66 KRW
Jan 1, 2019
-130.61 KRW
Jan 1, 2020
-36.24 KRW
Jan 1, 2021
-44.28 KRW
Jan 1, 2022
-82.24 KRW
Jan 1, 2023
-45.30 KRW
Jan 1, 2024
-40.92 KRW
Jan 1, 2025
-88.28 KRW
The Qurient Co ROE history
YEARROEYoY
-88.28 %+115.77%
-40.92 %-9.67%
-45.30 %-44.92%
-82.24 %+85.72%
-44.28 %+22.21%
-36.24 %-72.26%
-130.61 %+213.53%
-41.66 %-50.36%
-83.92 %+93.95%
-43.27 %-86.54%
-321.43 %-750.98%
49.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Qurient Co's Return on Equity (ROE)

Qurient Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Qurient Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Qurient Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Qurient Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Qurient Co stock

Return on Equity (ROE) of Qurient Co is -88.28 % in 2025.

Return on Equity (ROE) of Qurient Co changed from -40.92 % to -88.28 %, representing a 115.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Qurient Co

All Key Metrics — Qurient Co